Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Niagen Bioscience, Inc. Director's Dealing 2012

Jul 11, 2012

32418_dirs_2012-07-11_1df7de6c-1d31-4519-9e5a-31de807e12ef.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2012-07-09

Reporting Person: Brauser Michael (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-07-09 Common Stock A 500000 $0.00 Acquired 2599212 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 1860712 Indirect

Footnotes

F1: The restricted shares were awarded to compensate for the efforts on behalf of the Corporation.

F2: Indirect beneficial ownership includes: (i) 314,285 Shares held by Grander Holdings, Inc. 401K Profit Sharing Plan of which the Reporting Person is a trustee; (ii) 342,857 Shares held by the Brauser 2010 GRAT of which the Reporting Person is a trustee; (iii) 846,428 Shares held by BMB Holdings, LLLP of which the Reporting Person is the manager of its general partner; and (iv) 357,142 Shares held by Betsy Brauser Third Amended Trust Agreement beneficially owned by the Reporting Person's spouse which are disclaimed by him.